Palisade Bio Reports Third Quarter Financial Results
November 15, 2021 07:00 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help...
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders
October 22, 2021 08:00 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic...
Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 09, 2021 08:30 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Reports Second Quarter Financial Results and Provides Business Update
August 24, 2021 08:15 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic...
Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center
August 20, 2021 09:25 ET
|
Palisade Bio, Inc.
$5.2M invested at $3.45 stock priceFunds to be used to advance clinical development of LB1148Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used...
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
July 29, 2021 08:15 ET
|
Palisade Bio, Inc.
Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...
Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development
July 13, 2021 08:00 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions
June 15, 2021 08:15 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
May 13, 2021 07:00 ET
|
Palisade Bio, Inc.
LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery...
ニューラルステム、ケン･カーター博士を取締役会の常務会長に任命
December 19, 2018 02:04 ET
|
Neuralstem, Inc.
メリーランド州ジャーマンタウン発, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 神経幹細胞および小分子テクノロジーを基盤とする神経系治療の開発を専門にしているバイオ医薬品会社、ニューラルステム (Neuralstem, Inc.、Nasdaq: CUR) は本日、ケン･C･カーター博士 (Kenneth C. Carter, Ph.D.)...